Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Herantis Pharma
1950 investors follow this company
The company is not covered. See all listed companies from here.
BUY 6.90 LOWEST 7.00 VOLUME 879
SELL 7.35 HIGHEST 7.35 VALUE 0,006 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Latest insider trading

Type: stock_exchange_release
27.3.
2020

Herantis Pharma Plc
Company release 27 March 2020 at 1:00 PM Eastern European Time

Type: stock_exchange_release
24.3.
2020

Company will hold will hold a Capital Markets Day webcast on 24 March 2020 at 11:00 AM CET

Business operations including ongoing clinical trials and preparation for future studies continue as planned

Herantis Pharma Plc
Press release 24 March 2020 at 9:00 AM Eastern European Time

 

Herantis Pharma Plc ("Herantis" or "Company") announced today that a Capital Markets Day will be held through a webcast. In addition the Company provided  an update on its business operations during the COVID-19 (coronavirus) pandemic.

Type: stock_exchange_release
17.3.
2020

Herantis Pharma Plc
Company release 17 March 2020 at 9:00 am Eastern European Time

Herantis Pharma Plc's Annual Report for the year 2019 has been published today. The Annual Report contains financial statements and the report of the Board of Directors. The Annual Report is available in PDF format in Finnish and English as an appendix to this release and on the company's web site at http://herantis.com in section Investors - Financial information.

Type: stock_exchange_release
11.3.
2020

Notice to convene Herantis Pharma Plc's Annual General Meeting of shareholders

Herantis Pharma Plc
Company release 11 March 2020 at 9:00 AM Eastern European Time

NOTICE TO CONVENE herantis pharma PLC'S ANNUAL GENERAL MEETING OF SHAREHOLDERS

Type: stock_exchange_release
27.2.
2020

Looking forward to read-outs of fully recruited clinical studies

Herantis Pharma Plc
Company release, insider information 27 February 2020 at 5:00 PM Eastern European Time

Type: stock_exchange_release
25.2.
2020

Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020.

Herantis Pharma Plc
Company release, insider information 25 February 2020 at 9:00 AM Eastern European Time

Type: stock_exchange_release
30.12.
2019

Herantis Pharma Plc ("Herantis" or "Company") announced today an update on the development of its non-invasive next generation CDNF, or xCDNF. The xCDNF development program was initiated in July 2018 to develop cell-protecting molecules that penetrate the blood-brain barrier, building on the Company's cumulated expertise on CDNF, Herantis' lead compound in Parkinson disease.

Type: stock_exchange_release
20.12.
2019
Herantis Pharma Plc ("Herantis") will publish its Financial Statements in regard to 2019 on the 27[th] of February 2020. The financial reporting schedule of Herantis in 2020 is as follows:
  • Financial Statements bulletin in regard to 2019 on Thursday the 27[th] of February 2020
  • Interim Report on January-June 2020 on Thursday the 27[th] of August 2020

The Annual General Meeting is planned to be held on Wednesday the 8[th] of April 2020. The Board of Directors will present a formal notice at a later stage.

Type: stock_exchange_release
19.12.
2019

Herantis Pharma Plc ("Herantis" or "Company") announced today having completed patient treatments as planned in the main study of the Company's Phase 1-2 clinical trial examining Herantis' proprietary neuroprotective factor and novel drug candidate CDNF in patients with Parkinson's disease. Of the 17 patients randomized in the clinical trial, 15 patients completed the main study according to the study protocol and two patients discontinued due to reasons not related to CDNF.

Type: stock_exchange_release
17.12.
2019

Herantis Pharma Plc
Company release 17 Dec 2019 at 9:00 am

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Inveni Life Sciences Fund I Ky

Position: Closely associated person

(X) Legal person

(1):Person Discharging Managerial Responsibilities In Issuer

Name: Prihti, Aki

Position: Member of the Board

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Herantis Pharma

English translation unavailable for Herantis Pharma.
Herantis Pharma